Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06694636

Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma

Patients who met the inclusion criteria were treated with endovascular radiofrequency ablation and desympathetic nerve surgery. After enrollment, endovascular radiofrequency ablation and desympathetic surgery were performed. After radiofrequency ablation, the safety and efficacy of follow-up treatment will be carried out every 1 month or so, including blood routine, liver and kidney function, tumor indicators, abdominal CT/magnetic resonance, etc.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hepatocellular Carcinoma Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Age range

25 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinically or pathologically confirmed hepatocellular carcinoma (HCC)
  • Locally progressed or distant metastatic unresectable advanced HCC
  • Progressed after second-line therapy
  • Agree to participate in the study and sign the informed consent form

Exclusion criteria

  • Not suitable for ablation surgery
  • Pregnant, lactating and planning to become pregnant
  • Orthostatic hypotension
  • Mixed liver cancer
  • Intestinal obstruction
  • Obvious bleeding tendencies and hematologic diseases
  • Acute or severe systemic infection;
  • Stroke or transient ischemic attack (TIA) within two weeks;
  • Acute coronary syndrome within two weeks;
  • Evaluated to be not suitable for this trial by investigators

Treatment and study plan

endovascular radiofrequency ablation and desympathetic nerve surgery

Procedure

endovascular radiofrequency ablation and desympathetic nerve surgery

Primary outcomes

  1. ORR

    Time frame: every month, up to 1 year

    Objective Response Rate

Secondary outcomes

  1. PFS

    Time frame: every month, up to 1 year

    Progression Free Survival

  2. DCR

    Time frame: every month, up to 1 year

    disease control rate

Study contacts

Contact information is provided by the study sponsor or research team.

Hai-Dong Zhu

CONTACT

[email protected]

+86-25-83272121

Teng

CONTACT

Sponsors and collaborators

Lead sponsor

Zhongda Hospital

Other

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Nov 19, 2024
Registry last updated
Nov 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.